Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Takeda Pharma, H Lundbeck start MDD drug Phase III trial
In the trial, the companies will investigate the safety of Lu AA21004 (5 and 10 mg) compared to placebo. The primary endpoint of the Phase III trial is
In the trial, the companies will investigate the safety of Lu AA21004 (5 and 10 mg) compared to placebo. The primary endpoint of the Phase III trial is
The company’s loss from operations was $3.56m, compared to $4.57m for the same period last year. Total operating expenses for the first quarter ended 31 March 2011 were
The increase was primarily due to the amortization of deferred revenue from the upfront license fee received from our collaboration agreement with Norgine entered into in June 2010.
The drug pricing feature allows members to quickly determine the cost of their prescriptions, identify lower-cost alternatives and compare the costs of the prescription from multiple pharmacies and
The agreement has been signed between an affiliate of Elan and Paladin. As per the terms of the agreement, Paladin is responsible to an undisclosed upfront and milestone
Rapiscan, administered as a non-weight based bolus injection, is used as a pharmacological stress agent for radionuclide myocardial perfusion imaging (MPI) in adult patients unable to undergo adequate
Ultimate delivers solutions to a range of industries including pharmaceutical, manufacturing, logistics, chemical, healthcare and the public sector. Barts and London Trust, which consists of three hospitals; St
Aegis claims that Discoverant offers on-demand access, contextualization, analysis and reporting for all manufacturing, quality and process development data. Under the agreement, Shire will utilize Discoverant to manage
NEO-301 specifically binds a variant of the A33 tumor antigen which is a target expressed on the majority of colorectal cancers, and was also found to be expressed
The Series A financing has been led by Adams Street Partners and Latterell Venture Partners. GLYX-13 is a glycine-site functional partial agonist (GFPA) selective modulator of the NMDA